Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test

Pharmacogenet Genomics. 2011 Dec;21(12):894-901. doi: 10.1097/FPC.0b013e32834bec2b.

Abstract

N-acetyltransferase 2 (NAT2) catalyzes the bioactivation and/or detoxification of drugs and carcinogens. The aim of this study was to establish the correlation between the NAT2 genotype and the acetylating phenotype in a Mexican population using sulfamethazine as a probe. From a total of 122 individuals, 73 (59.8%) were slow and 49 (40.2%) were fast acetylators. Eleven individuals (9%) had the wild-type genotype (NAT2*4/NAT2*4). The most frequent genotype was NAT2*4/NAT2*5B observed in 20.66% of individuals. In conclusion, our results show that an accurate prediction of the acetylation phenotype by genotyping can be achieved in around half of the population. Further studies with a larger number of individuals are required to establish correlations between phenotype and genotype in half of that patients having a genotype combined with slow/rapid alleles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation
  • Adult
  • Aged
  • Alleles
  • Arylamine N-Acetyltransferase / genetics*
  • Arylamine N-Acetyltransferase / metabolism
  • Carcinogens / pharmacology*
  • Female
  • Genetic Association Studies
  • Humans
  • Male
  • Mexico
  • Middle Aged
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Polymorphism, Genetic*
  • Sulfamethazine / pharmacokinetics*

Substances

  • Carcinogens
  • Sulfamethazine
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human